Document:

Exhibit 4.2

 

THIS WARRANT AND THE UNDERLYING SECURITIES
HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE
STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.

 

REGENERX BIOPHARMACEUTICALS, INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

October 19, 2012

 

Void After October 19, 2017

 

THIS CERTIFIES THAT,
for value received, _____________, or his/its permitted registered assigns (the “Holder”), is
entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware
corporation (the “Company”) up to ________ shares of the common stock
of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant
to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase
Agreement”).

 

		1.	DEFINITIONS.

 

Capitalized terms used
herein but not otherwise defined herein shall have their respective meanings as set forth in the Purchase Agreement. As used herein,
the following terms shall have the following respective meanings:

 

(a)               
“Business Day” means a day, other than a Saturday or Sunday, on which banks in New York
City are open for the general transaction of business.

 

(b)              
“Exercise Period” shall mean the period commencing with the date that is six months after
the date hereof and ending at 5:30 p.m. New York City time on the fifth (5th) anniversary of the date hereof.

 

(c)               
“Exercise Price” shall mean $0.15 per share, subject to adjustment pursuant to Section
5 below.

 

(d)              
“Exercise Date” shall have the meaning set forth in Section 3.1(b) hereof.

 

(e)               
“Exercise Shares” shall mean the shares of Common Stock issuable upon exercise of this
Warrant.

 

    	 

    	 

    

 

(f)               
“Expiration Date” shall mean 5:30 p.m. New York City time on the fifth (5th)
anniversary of the date hereof.

 

(g)              
“Trading Day” shall mean (i) any day on which the Common Stock is listed or quoted and
traded on its primary Trading Market, (ii) if the Common Stock is not then listed or quoted and traded on any Trading Market, then
a day on which trading occurs on the OTC Bulletin Board (or any successor thereto), or (iii) if trading does not occur on the OTC
Bulletin Board (or any successor thereto), any Business Day.

 

(h)              
“Trading Market” means whichever of the New York Stock Exchange, the NYSE Amex, the NASDAQ
Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is
listed or quoted for trading on the date in question.

 

		2.	Reserved.

 

		3.	EXERCISE OF WARRANT.

 

3.1.           
Exercise of Warrant.

 

(a)               
The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period
upon (i) delivery of an executed Notice of Exercise in the form attached hereto to the Company at its address set forth on the
signature page hereto (or at such other address as it may designate by notice in writing to the Holder), (ii) surrender of this
Warrant and (iii) payment of the Exercise Price for the number of Exercise Shares as to which this Warrant is being exercised.
The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above shall constitute
the Holder’s certification to the Company that his/its representations contained in Section 4.2(b), (c) and (d) of
the Purchase Agreement are true and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee
Holder that is not a party to the Purchase Agreement, such transferee Holder’s certification to the Company that such representations
are true and correct as to such assignee Holder as of the Exercise Date).

 

(b)              
With respect to each exercise of this Warrant pursuant to Section 3.1(a) above, the Exercise Date shall be deemed
to be the date the Exercise Price is received by the Company. The Exercise Shares shall be deemed to have been issued, and Holder
or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all
purposes, as of the Exercise Date. The person in whose name any certificate or certificates for Exercise Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the Exercise Date, irrespective
of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when
the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the
close of business on the next succeeding date on which the stock transfer books are open.

 

(c)               
Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder
by crediting the account of the Holder’s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent
Commission system if the Company is a participant in such system, and otherwise by physical delivery to the address specified by
the Holder in the Notice of Exercise within three business days from the delivery to the Company of the Notice of Exercise, surrender
of this Warrant and payment of the aggregate Exercise Price as set forth above.

 

    	 

    	 

    

 

3.2.           
Issuance of New Warrants. Upon any partial exercise of this Warrant, the Company, at its expense, will
forthwith and, in any event within five business days, issue and deliver to the Holder a new warrant or warrants of like tenor,
registered in the name of the Holder, exercisable, in the aggregate, for the balance of the number of shares of Common Stock remaining
available for purchase under the Warrant.

 

3.3.           
Payment of Taxes and Expenses. The Company shall pay any recording, filing, stamp or similar tax which
may be payable in respect of any transfer involved in the issuance of, and the preparation and delivery of certificates (if applicable)
representing, (i) any Exercise Shares purchased upon exercise of this Warrant and/or (ii) new or replacement warrants in the Holder’s
name or the name of any transferee of all or any portion of this Warrant.

 

		4.	COVENANTS OF THE COMPANY.

 

4.1.           
Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be
issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully
paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants
and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights,
a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any
time during the Exercise Period the number of authorized but unissued shares of Common Stock shall not be sufficient to permit
exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase
its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.

 

4.2.           
No Impairment. Except to the extent as waived or consented to by the Holder, the Company will not, by
amendment of its Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the
provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect the exercise
rights of the Holder against impairment.

 

4.3.           
Notices of Record Date and Certain Other Events. In the event of any taking by the Company of a record
of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend
(other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Company shall
mail to the Holder, at least 10 days prior to the date on which any such record is to be taken for the purpose of such dividend
or distribution, a notice specifying such date.

 

    	 

    	 

    

 

 

		5.	ADJUSTMENT OF EXERCISE PRICE AND EXERCISE SHARES.

 

(a)               
In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations,
reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, consolidation, acquisition
of the Company, or the like, the number, class and type of shares available under the Warrant in the aggregate and the Exercise
Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the
total number, class, and type of shares or other property as the Holder would have owned had the Warrant been exercised prior to
the event and had the Holder continued to hold such shares until the event requiring adjustment. The form of this Warrant need
not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.

 

(b)              
If at any time following delivery by Holder to the Company of a Notice of Exercise but prior to issuance of the applicable
Exercise Shares, the holders of Common Stock of the Company (or any shares of stock or other securities at the time receivable
upon the exercise of this Warrant) shall have received or become entitled to receive, without payment therefor:

 

(i)                
Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible
into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing
by way of dividend or other distribution (other than a dividend or distribution covered in Section 5(a) above),

 

(ii)              
any cash paid or payable otherwise than as a cash dividend, or

 

(iii)            
Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification,
combination of shares or similar corporate rearrangement (other than shares of Common Stock pursuant to Section 5(a) above),

 

then and in each
such case, the Holder hereof will be entitled to receive, in addition to the number of shares of Common Stock receivable pursuant
to the Notice of Exercise, and without payment of any additional consideration therefor, the amount of stock and other securities
and property (including cash in the cases referred to in clauses (ii) and (iii) above) which such Holder would hold on the date
of such exercise had such Holder been the holder of record of such Common Stock as of the date on which holders of Common Stock
received or became entitled to receive such shares or all other additional stock and other securities and property.

 

(c)               
Upon the occurrence of each adjustment pursuant to this Section 5, the Company at its expense will, at the written
request of the Holder, promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate
setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares
or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a
copy of each such certificate to the Holder and to the Company’s transfer agent.

 

    	 

    	 

    

 

		6.	FRACTIONAL SHARES.

 

No fractional shares
shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result
in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share,
the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash
equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction.

 

		7.	NO STOCKHOLDER RIGHTS.

 

Other than as provided
in Section 3.1(a) or otherwise herein, this Warrant in and of itself shall not entitle the Holder to any voting rights or other
rights as a stockholder of the Company.

 

		8.	TRANSFER OF WARRANT.

 

Subject to applicable
laws and the restrictions on transfer set forth on the first page of this Warrant and set forth in the Purchase Agreement, including,
without limitation, Section 4 thereof, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly
authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder.
The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company and its counsel.

 

		9.	LOST, STOLEN, MUTILATED OR DESTROYED WARRANT.

 

If this Warrant is
lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which
shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as
the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of
the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

		10.	NOTICES, ETC.

 

All notices required
or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be
notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on
the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address listed on the signature page hereto and
to Holder at the applicable address set forth on the applicable signature page to the Purchase Agreement or at such other address
as the Company or Holder may designate by 10 days advance written notice to the other parties hereto.

 

    	 

    	 

    

 

		11.	ACCEPTANCE.

 

Receipt of this Warrant
by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

		12.	GOVERNING LAW.

 

This Warrant and all
rights, obligations and liabilities hereunder shall be governed by the laws of the State of Delaware.

 

		13.	AMENDMENT OR WAIVER.

 

Any term of this Warrant
may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written
consent of the Company and the Holder. No waivers of any term, condition or provision of this Warrant, in any one or more instances,
shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its duly authorized officer as of October 19, 2012.

 

 

	 	REGENERX BIOPHARMACEUTICALS, INC.
	 	 
	 	By: 	
	 	 	Name: J.J. Finkelstein
Title: President and Chief Executive Officer

 

    	 

    	 

    
  

NOTICE OF EXERCISE

 

TO: REGENERX BIOPHARMACEUTICALS, INC.

 

(1)The undersigned
hereby elects to purchase shares of the Common Stock of REGENERX BIOPHARMACEUTICALS, INC. (the “Company”)
pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.

 

(2)Please issue
a certificate or certificates representing said shares of Common Stock of the Company in the name of the undersigned or in such
other name as is specified below:

 

(Name)

 

(Address)

 

(3)The undersigned
represents that (i) the aforesaid shares of Common Stock are being acquired for the account of the undersigned and not with a
view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing
or reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and financial condition
and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding his/its investment
in the Company; (iii) the undersigned is experienced in making investments of this type and has such knowledge and background
in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting
the undersigned’s own interests; (iv) the undersigned understands that the shares of Common Stock issuable upon exercise
of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”),
by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among
other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered
under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption
from such registration is available; (v) the undersigned is aware that the aforesaid shares of Common Stock may not be sold pursuant
to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for
the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information
to the public about the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid
shares of Common Stock unless and until there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided
upon the Company’s reasonable request, an opinion of counsel satisfactory to the Company, stating that such registration
is not required.

 

	(Date)	(Signature)
	 	 
	 	(Print name)

 

    	 

    	 

    

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form
and supply required information.

Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to

 

	Name:	_____________________________
	 	(Please Print)
	 	
	Address:	_____________________________
	 	(Please Print)

 

 

Dated:                         , 20

 

Holder’s Signature:

 

Holder’s Address:

 

  

 

 

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Warrant.Exhibit 10.1

 

   

REGENERX BIOPHARMACEUTICALS, INC.

 

 

 

 

______________________________

 

 

 

 

 

CONVERTIBLE NOTE AND WARRANT PURCHASE
AGREEMENT

 

 

 

OCTOBER 19,
2012

 

 

 

    	 

    	 	

    
 

Table of Contents

 

	 	 	 	Page
	 	 	 	 
	SECTION 1.	 	DEFINITIONS	1
	 	 	 	 
	SECTION 2.	 	ISSUANCE AND SALE OF THE SECURITIES	3
	 	 	 	 
	SECTION 3.	 	THE CLOSING	3
	 	 	 	 
	3.1	 	Closing	3
	3.2	 	Deliveries by the Company	4
	3.3	 	Deliveries by the Investor	4
	 	 	 	 
	SECTION 4.	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	4
	 	 	 	 
	4.1	 	Representations and Warranties of the Company	4
	4.2	 	Representations and Warranties of the Investor	6
	 	 	 	 
	SECTION 5.	 	CONDITIONS TO CLOSING	8
	 	 	 	 
	5.1	 	Conditions to Closing by the Investor	8
	5.2	 	Conditions to Closing by the Company	8
	 	 	 	 
	SECTION 6.	 	MISCELLANEOUS	9
	 	 	 	 
	6.1	 	Waivers and Amendments	9
	6.2	 	Costs and Expenses	9
	6.3	 	Remedies Cumulative	9
	6.4	 	Remedies Not Waived	9
	6.5	 	Entire Agreement	10
	6.6	 	Specific Performance	10
	6.7	 	Governing Law	10
	6.8	 	Notices	10
	6.9	 	Counterparts	11
	6.10	 	Successors and Assigns	11
	6.11	 	Third Parties	11
	6.12	 	Schedules and Exhibits	11
	6.13	 	Headings	11

    

    	-i-

    	 

    
  

CONVERTIBLE NOTE AND WARRANT PURCHASE
AGREEMENT

 

THIS
CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of October 19,
2012, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the
“Company”), and ______________________
(the “Investor”).

 

RECITALS

 

Whereas,
the Company has authorized the sale and issuance of (i) convertible promissory notes in the form attached hereto as Exhibit
A the aggregate principal amount of $300,000 (the “Notes”) (the securities issuable on
conversion of the Notes, the “Conversion Shares”) and (ii) warrants, in substantially the form
attached hereto as Exhibit B
(the “Warrant”), to purchase an aggregate of 400,000  shares of its Common Stock (the
“Warrant Shares” and, along with the Conversion Shares, the Warrants and the Notes, the
“Securities”) for an aggregate purchase amount of $300,000, pursuant to the terms of a series of
Agreements on substantially identical terms to this Agreement;

 

Whereas,
the Investor desires to purchase the Securities on the terms and conditions set forth herein; and

 

Whereas,
the Company desires to issue and sell the Securities to the Investor on the terms and conditions set forth herein.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:

 

		SECTION 1. 	DEFINITIONS

 

The following terms
when used in this Agreement shall have the following respective meanings:

 

“Applicable
Laws” has the meaning set forth in Section 4.1(f) hereof.

 

“Board
of Directors” means the Board of Directors of the Company.

 

“Capital
Stock” means (i) with respect to any Person that is a corporation, any and all shares, interests or equivalents in
capital stock (whether voting or nonvoting and whether common or preferred) of such corporation and (ii) with respect to any Person
that is not a corporation, any and all partnership, membership, limited liability company or other equity interests of such Person;
and in each case, any and all warrants, rights or options to purchase any of the foregoing.

 

    	1

    	 

    
 

 

“Certificate
of Incorporation” means the Certificate of Incorporation of the Company, as in effect and on file with the Secretary
of State of the State of Delaware on the date of this Agreement.

 

“Closing”
has the meaning set forth in Section 3.1 hereof.

 

“Closing
Date” has the meaning set forth in Section 3.1 hereof.

 

“Common
Stock” means the Common Stock of the Company, par value $0.001 per share.

 

“Conversion
Shares” has the meaning set forth in the Preamble.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Governmental
Authority” means the United States, any state, county or municipality, the government of any foreign country, any
subdivision of any of the foregoing or any authority, department, commission, board, bureau, agency, court or instrumentality of
any of the foregoing.

  

“Knowledge
of the Company,” including the terms “Know,” “Known” and other
derivatives thereof, means, with respect to the Company, the actual knowledge, after reasonable investigation, of any Responsible
Officer.

 

“Lien”
means any mortgage, lien, pledge, security interest, easement, conditional sale or other title retention agreement or other encumbrance
of any kind except for liens relating to taxes that have accrued but are not yet payable which do not have a Material Adverse Effect.

 

“Material
Adverse Effect” means a material adverse effect upon (i) the condition (financial or otherwise), operations, business,
properties or assets of the Company, (ii) the ability of the Company to perform its obligations under this Agreement or any of
the other agreements or documents contemplated hereby to which it is a party or (iii) the legality, validity or enforceability
of this Agreement or any of the other agreements or documents contemplated hereby or the rights and remedies of the Investor and
the other parties hereunder and thereunder.

 

“Material
Agreements” has the meaning set forth in Section 4.1(e) hereof.

 

“Notes”
has the meaning set forth in the Preamble.

 

“Parties”
refers collectively to the Company and the Investor.

 

“Person”
means an individual, corporation, partnership, joint venture, trust, unincorporated organization, or Governmental Authority.

 

“Purchase
Price” has the meaning set forth in Section 2 hereof.

 

“Regulation
D” has the meaning set forth in Section 4.2(c) hereof.

 

    	2

    	 

    
 

 

“Responsible
Officer” means, with respect to the Company, the President and Chief Executive Officer, the Vice President of Clinical
and Regulatory Affairs or the Chairman of the Board of Directors.

 

“Returns”
has the meaning set forth in Section 4.1(i) hereof.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“SEC Reports”
has the meaning set forth in Section 4.1(h)(i) hereof.

 

“Securities”
has the meaning set forth in the Preamble.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

 

“Stockholders”
has the meaning set forth in Section 4.1(b) hereof.

 

“Tax”
or “Taxes” refers to any and all federal, state, national, local, foreign and other taxes, assessments
and other governmental charges, duties, levies, impositions and liabilities relating to taxes, including taxes based upon or measured
by gross receipts, income, profits, sales, use and occupation, and value added, ad valorem, transfer, franchise, withholding, payroll,
recapture, employment, excise and property taxes, together with all interest, penalties and additions imposed with respect to such
amounts and any obligations under any agreements or arrangements with any other person with respect to such amounts and including
any liability for taxes of a predecessor entity.

 

“Warrant”
has the meaning set forth in the Preamble.

 

“Warrant
Shares” has the meaning set forth in the Preamble.

 

		SECTION
                            2.	ISSUANCE AND SALE OF THE SECURITIES

 

At the Closing, the
Company shall issue and sell to the Investor, and such Investor shall purchase, for an aggregate purchase price of $[_________]
(the “Purchase Price”), from the Company, (i) a Note in the principal amount of $[_____]
and (ii) a Warrant to purchase ________ Warrant Shares at an exercise price of $0.__ per share (the number of Warrant Shares
is determined by the dividing the Purchase Price by the exercise price per share of the Warrant, and multiplying the resulting
quotient by 20%).

 

		SECTION
                            3.	THE CLOSING

 

3.1             
Closing 

 

The
closing of the issuance and sale of the Securities pursuant to Section 2 hereof and certain of the other transactions contemplated
hereby (the “Closing”) shall take place at the offices of Cooley LLP, One Freedom Square, Reston
Town Center, 11951 Freedom Drive, Reston, Virginia 20190, within one business day following the satisfaction
of the conditions specified in Section 8 below, or at such other time or place as the Parties shall mutually agree (the actual
date being referred to herein as the “Closing Date”). The Parties agree that the Closing may occur by
facsimile signature and delivery and that the Parties need not appear in person at the Closing.

 

    	3

    	 

    
 

 

3.2             
Deliveries by the Company

 

At or prior to the
Closing, the Company shall deliver or cause to be delivered to the Investor the following items:

 

(a)               
The Note purchased by the Investor hereunder, registered in the name of the Investor and subject to the legends and other
restrictions set forth herein;

 

(b)              
a Warrant, executed by the Company and registered in the name of the Investor, pursuant to which the Investor shall have
the right to acquire the Warrant Shares issuable to the Investor pursuant to Section 2 on the terms set forth therein;

 

(c)               
a certificate of the Secretary or Assistant Secretary of the Company, in form and substance satisfactory to counsel for
the Investor, certifying that attached thereto are true and correct copies of (i) the bylaws of the Company, and (ii) resolutions
duly and validly adopted by the Board of Directors authorizing the allotment and issuance of the Securities to the Investor, execution
and delivery of this Agreement and the consummation of the transactions contemplated hereby; and

 

(d)              
a counterpart of this Agreement duly executed by the Company. 

 

3.3             
Deliveries by the Investor

 

At or prior to the
Closing, the Investor shall deliver or cause to be delivered to the Company the following items:

 

(a)               
payment of the Purchase Price in immediately available funds by wire transfer to an account designated in writing by the
Company prior to the Closing Date;

 

(b)              
a fully completed and duly executed Accredited Investor Certification in the form attached hereto as Exhibit
C; and

 

(c)               
a counterpart of this Agreement duly executed by the Investor.

 

		SECTION
                            4.	REPRESENTATIONS, WARRANTIES AND COVENANTS

 

4.1             
Representations and Warranties of the Company

 

In order to induce the Investor to purchase
the Securities it is purchasing hereunder, the Company represents and warrants to the Investor as of the date hereof that:

 

(a)               
Organization and Standing. The Company is duly incorporated and validly existing under the laws of the State of Delaware
and has all requisite corporate power and authority to own or lease its properties and assets and to conduct its business as it
is presently being conducted.

 

    	4

    	 

    
 

 

(b)              
Capitalization. Immediately subsequent to the consummation of the transactions contemplated by this Agreement, the
authorized Capital Stock of the Company shall be as set forth on Schedule 4.1(b) hereto. The outstanding shares of Capital
Stock are all duly and validly authorized and issued, fully paid and nonassessable, and based in part on the representations of
the stockholders of the Company (the “Stockholders”) made in connection with the issuance thereof, were
issued in compliance with all applicable federal and state securities laws.

 

(c)               
Capacity of the Company; Consents; Execution of Agreements. The Company has all requisite power, authority and capacity
to enter into this Agreement and to perform the transactions and obligations to be performed by it hereunder. The execution and
delivery of this Agreement and any agreements contemplated hereby by the Company, and the performance by the Company of the transactions
and obligations contemplated hereby and thereby, including, without limitation, the issuance and delivery of the Securities to
the Investor, has been duly authorized by all requisite action of the Company and Stockholders. This Agreement has been duly executed
and delivered by a duly authorized officer of the Company and constitutes a valid and legally binding agreement of the Company,
enforceable in accordance with its respective terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium or other similar laws of the United States (both state and federal), affecting the enforcement of creditors’ rights
or remedies in general and general equity principles.

 

(d)              
Status of the Conversion Shares and Warrant Shares; Reservation of Common Stock. The Conversion Shares and Warrant
Shares to be issued and purchased hereunder, when issued by the Company to the Investor and paid for by the Investor pursuant to
the terms of this Agreement and the Note and Warrant, respectively, will (i) be duly authorized, validly issued, fully paid and
nonassessable, (ii) based on the Investor’s representations in Section 4.2, have been issued in compliance with all applicable
United States federal and state securities laws and (iii) be free and clear of all Liens. The Company has available sufficient
shares of Common Stock for issuance pursuant to the terms of this Agreement.

 

(e)               
Conflicts; Defaults. The execution and delivery of this Agreement by the Company and the performance by the Company
of the transactions and obligations contemplated hereby to be performed by it will not (i) materially violate, conflict with, or
constitute a default under any of the terms or provisions of, the Certificate of Incorporation, the bylaws, or any provisions of,
or result in the acceleration of any obligation under, any material contract, note, debt instrument, security agreement, or other
instrument to which the Company is a party or by which the Company, or any of their assets is bound (collectively, the “Material
Agreements”); (ii) result in the creation or imposition of any Liens or claims upon the Company’s assets or
upon the Company’s Common Stock; (iii) assuming the accuracy of the Investor’s representations in Section 4.2, constitute
a material violation of any law, statute, judgment, decree, order, rule, or regulation of a Governmental Authority applicable to
the Company; or (iv) constitute an event which, after notice or lapse of time or both, would result in any of the foregoing. The
Company is not presently in violation of its Certificate of Incorporation or bylaws.

 

    	5

    	 

    
 

 

(f)               
Compliance with Laws. The Company is not in violation of, nor do any of its respective operations violate in any
respect, any statute, law, or regulation of any Governmental Authority applicable to the Company (“Applicable Laws”),
which violation would have a Material Adverse Effect.

 

(g)              
Litigation. As of the date hereof: (i) the Company is not subject to any order of, or written agreement or memorandum
of understanding with, any Governmental Authority which would have a Material Adverse Effect; (ii) there are no material actions,
suits, claims, investigations, or proceedings pending at law or in equity or before or by any Governmental Authority, or, to the
Knowledge of the Company, threatened, against the Company or any of its assets or properties or the transactions contemplated by
this Agreement, and to the Knowledge of the Company, there exist no facts or circumstances which reasonably could be anticipated
to result in any such action, suit, claim, investigation, or proceeding; and (iii) no Person has asserted, and, to the Knowledge
of the Company, no Person has a valid basis upon which to assert, any claims against the Company that would materially adversely
affect the transactions contemplated by this Agreement or result in or form the basis of any such action, suit, claim, investigation
or proceeding. There is no material action, suit, proceeding or investigation by the Company currently pending or which the Company
intends to initiate.

 

(h)              
Securities Laws.

 

(i)                
The Company has filed all forms, reports and documents with the SEC required to be filed by it pursuant to the federal securities
laws and the SEC rules and regulations thereunder, all of which complied in all material respects with all applicable requirements
of the Securities Act and the Exchange Act (collectively, the “SEC Reports”). None of the SEC Reports,
including, without limitation, any financial statements or schedules included therein, at the time filed (or if amended or superseded
by a filing prior to the date of this Agreement, then on the date of such filing) contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of circumstances under which they were made, not misleading.

 

(ii)              
Based on the Investor’s representations in Section 4.2, no consent, authorization, approval, permit, or order of or
filing with any Governmental Authority is required in order for the Company to execute and deliver this Agreement or in order for
the Company to offer, issue, sell, or deliver the Securities. Based in part on the representations of the Investor and under the
circumstances contemplated hereby and under current laws and regulations, the offer, issuance, sale and delivery of the Securities
to the Investor is exempt from the registration requirements of the Securities Act.

 

(i)                
Taxes. The Company has timely filed or caused to be filed with the appropriate taxing authority all federal, state,
national, local and foreign returns, estimates, information statements and reports (“Returns”) relating
to Taxes required to be filed by the Company on or prior to the Closing Date. The Returns have accurately reflected in all material
respects and will accurately reflect in all material respects all liability for Taxes of the Company for the periods covered thereby.

 

4.2             
Representations and Warranties of the Investor

 

The Investor hereby represents and warrants
to the Company that as of the date hereof:

 

    	6

    	 

    
 

 

(a)               
Investment Intent. The Securities to be purchased by the Investor hereunder are being purchased for its own account
and not with the view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the
Securities Act. The Investor understands that the Securities have not been registered under the Securities Act by reason of their
issuance in transactions exempt from the registration and prospectus delivery requirements of the Securities Act pursuant to Section
4(a)(2) thereof. The Investor further understands that the certificates representing the Conversion Shares and any Warrant Shares
that may be issued pursuant to the conversion of the Note and exercise of the Warrant, respectively, will bear the following legend
and the Investor agrees that it will hold such shares subject thereto:

 

“THESE SECURITIES HAVE
NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE
SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.”

 

(b)              
Capacity of the Investor; Execution of Agreement. The Investor has all requisite power, authority and capacity to
enter into this Agreement, deliver the Purchase Price, and to perform the transactions and obligations to be performed by it hereunder.
This Agreement has been duly authorized, executed and delivered by them and constitutes its valid and legally binding obligation,
enforceable in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium or other similar laws, both state and federal, affecting the enforcement of creditors’ rights or remedies in general
from time to time in effect and the exercise by courts of equity powers or their application of principles of public policy.

 

(c)               
Accredited Investor. The Investor is an “accredited investor” as defined in Rule 501(a) of Regulation
D promulgated under the Securities Act (“Regulation D”).

 

(d)              
Suitability and Sophistication. (i) The Investor has such knowledge and experience in financial and business matters
that it is capable of independently evaluating the risks and merits of purchasing the Securities; (ii) the Investor has independently
evaluated the risks and merits of purchasing the Securities and has independently determined that the Securities are a suitable
investment for it; and (iii) the Investor has sufficient financial resources to bear the loss of their entire investment in the
Securities.

 

    	7

    	 

    
 

 

(e)               
Receipt of Information. The Investor believes, after due inquiry and investigation, that it has received all of the
information that it considers necessary or appropriate for deciding whether to purchase the Securities. The Investor further represents
that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the
offering of the Securities and the business, properties, prospects and financial condition of the Company and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary
to verify the accuracy of any information furnished to the Investor. The foregoing, however, does not limit or modify the representations
and warranties of the Company in Section 4 of this Agreement or the right of the Investor to rely thereon.

 

(f)               
Independent Existence. The Investor was not formed for the specific purpose of purchasing the Securities.

 

		SECTION
                            5.	CONDITIONS TO CLOSING

 

5.1             
Conditions to Closing by the Investor

 

The obligations of
the Investor to consummate the purchase of the Securities pursuant to Section 2 hereof and certain of the transactions contemplated
by this Agreement are subject to the satisfaction on or prior to the Closing Date of the following conditions, any of which may
be waived in whole or in part in writing by the Investor: 

 

(a)               
all representations and warranties of the Company contained in this Agreement shall be true and correct as of the date of
this Agreement and as of the Closing Date as though made anew as of such date (unless another date is specified);

 

(b)              
the Company shall have delivered to the Investor the items required by Section 3.2 of this Agreement;

 

(c)               
the Company shall have performed and complied with all agreements and conditions required by this Agreement to be performed
and complied with by it prior to or as of the Closing Date; and

 

(d)              
all pre-issuance registrations, qualifications, permits and approvals required, if any, under
applicable state securities laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the
offer, sale, issuance and delivery of the Securities shall have been obtained.

 

5.2             
Conditions to Closing by the Company

 

The obligations of
the Company to consummate the issuance and sale of the Securities pursuant to Section 2 hereof and certain of the transactions
contemplated by this Agreement are subject to the satisfaction on or prior to the Closing Date of the following conditions, any
of which may be waived in whole or in part in writing by the Company:

 

(a)               
all representations and warranties of the Investor contained in this Agreement shall be true and correct as of the date
of this Agreement and as of the Closing Date as though made anew as of such date;

 

    	8

    	 

    
 

 

(b)              
the Investor shall have delivered to the Company the items required by Section 3.3 of this Agreement;

 

(c)               
all pre-issuance registrations, qualifications, permits and approvals required, if any, under applicable state securities
laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the offer, sale, issuance and
delivery of the Securities shall have been obtained; and

 

(d)              
the Investor shall have performed and complied with all agreements and conditions required by this Agreement to be performed
and complied with by it prior to or as of the Closing Date.

 

		SECTION
                            6.	MISCELLANEOUS

 

6.1             
Waivers and Amendments

 

This Agreement may
be amended or modified in whole or in part only by a writing which makes reference to this Agreement that is executed by the Investor
and the Company. The obligations of any Party hereunder may be waived (either generally or in a particular instance and either
retroactively or prospectively) only with the written consent of the party claimed to have given the waiver; provided, however,
that any waiver by any party of any violation of, breach of, or default under any provision of this Agreement or any other agreement
provided for herein shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation
of, breach of or default under any other provision of this Agreement or any other agreement provided for herein.

 

6.2             
Costs and Expenses

 

Each party agrees to
pay its own costs and expenses in connection with the preparation, execution and delivery of this Agreement and other instruments
and documents to be delivered hereunder and thereunder.

 

6.3             
Remedies Cumulative

 

No specific right,
power, or remedy conferred by this Agreement shall be exclusive, and each such right, power, or remedy shall be cumulative and
in addition to every other right, power, or remedy, whether conferred hereby or by any security of the Company or now or hereafter
available, at law or in equity, by statute or otherwise.

 

6.4             
Remedies Not Waived

 

No course of dealing
between the Company and the Investor, and no delay in exercising any right, power, or remedy conferred hereby or by any security
issued by the Company, or now or hereafter available at law or in equity, by statute or otherwise, shall operate as a waiver of
or otherwise prejudice any such right, power, or remedy.

 

    	9

    	 

    
 

 

6.5             
Entire Agreement

 

This Agreement and
the other agreements and instruments expressly provided for herein, together set forth the entire understanding of the parties
hereto and supersede in their entirety all prior contracts, agreements, arrangements, communications, discussions, representations
and warranties, whether oral or written, among the parties with respect to the subject matter hereof.

 

6.6             
Specific Performance

 

The Company and the
Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were
not performed in accordance with the specific terms hereof or were otherwise breached. It is accordingly agreed that, to the fullest
extent permitted by law or equity, each of the parties shall be entitled to an injunction or injunctions to prevent or cure breaches
of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any
other remedy to which the parties may be entitled by law or equity.

 

6.7             
Governing Law

 

This Agreement shall
in all respects be governed by and construed in accordance with the internal substantive laws of the State of Delaware without
giving effect to the principles of conflicts of law thereof.

 

6.8             
Notices

 

Any notice, request
or other communication required or permitted hereunder shall be in writing and be deemed to have been duly given (a) when personally
delivered or sent by facsimile transmission (the receipt of which is confirmed in writing), (b) one business day after being sent
by a nationally recognized overnight courier service or (c) three business days after being sent by registered or certified mail,
return receipt requested, postage prepaid, to the parties at their respective addresses set forth below.

 

If to the Company:

 

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road

Suite 470

Rockville, MD 20850

Attention: J.J. Finkelstein

Facsimile: 301-208-9194

 

With a copy, which shall not constitute
notice, to:

Cooley LLP

One Freedom Square, Reston Town Center

11951 Freedom Drive

Reston, VA 20190

Attention: Darren K. DeStefano, Esq.

Facsimile: 703-456-8100

 

    	10

    	 

    
 

 

If to the Investor:

 

To the address set forth below the Investor’s
name on the signature page of this Agreement

 

Any party by written notice to the others
may change the address or the persons to whom notices or copies thereof shall be directed.

 

6.9             
Counterparts

 

This Agreement may
be executed in counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and
the same instrument.

 

6.10         
Successors and Assigns

 

This Agreement shall
be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

 

6.11         
Third Parties

 

Nothing expressed or
implied in this Agreement is intended, or shall be construed, to confer upon or give any Person other than the parties hereto any
rights or remedies under or by reason of this Agreement.

 

6.12         
Schedules and Exhibits

 

The schedules and exhibits
attached to this Agreement are incorporated herein and shall be part of this Agreement for all purposes.

 

6.13         
Headings

 

The headings in this
Agreement are solely for convenience of reference and shall not be given any effect in the construction or interpretation of this
Agreement.

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 

    	11

    	 

    
 

IN WITNESS WHEREOF,
the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase
Agreement as of the date first above written.

 

REGENERX BIOPHARMACEUTICALS, INC.

 

By:______________________________

Name:J.J. Finkelstein

Title:President and Chief Executive
Officer

 

    	12

    	 

    
 

 

IN WITNESS WHEREOF,
the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase
Agreement as of the date first above written.

 

 

Name of Purchaser: __________________________

 

Signature of Authorized Signatory of
Purchaser: _________________________________

 

Name of Authorized Signatory: _________________

 

Title of Authorized Signatory: _______

 

Email Address of Authorized Signatory:
__________________

 

Facsimile Number of Authorized Signatory: __________________________

 

Address for Notice of Purchaser:

 

___________________________________________

 

Address for Delivery of Securities for Purchaser (if not same
as address for notice):

 

____________________________________________

 

    	13

    	 

    
 

 

Exhibit
A

 

FORM OF NOTE

 

See Exhibit 4.1

 

    	14

    	 

    
 

 

EXHIBIT B

 

FORM OF WARRANT

 

See Exhibit 4.2

 

    	15

    	 

    
 

 

Exhibit
C

 

ACCREDITED INVESTOR CERTIFICATION

 

The undersigned represents and warrants
to RegeneRx Biopharmaceuticals, Inc. (the “Company”) that the undersigned fits within each category marked
below, and that for any category marked, he, she or it has truthfully set forth any description required as provided for below.
ALL INFORMATION WILL BE KEPT STRICTLY CONFIDENTIAL. The undersigned agrees to furnish any additional information that the Company
deems necessary in order to verify the answers set forth below.

 

(PLEASE MARK EACH CATEGORY APPLICABLE TO YOU)

 

		 ̈	The undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth,
or joint net worth with his or her spouse, presently exceeds $1,000,000.

 

			Explanation. In calculating net worth you may include equity in personal property and real
estate, including your principal residence, cash, short-term investments, stock and securities. Equity in personal property and
real estate should be based on the fair market value of such property minus debt secured by such property.

 

		 ̈	The undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess
of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those
years (in each case, including foreign income, tax exempt income and full amount of capital gains and losses, but excluding any
income of other family members and any unrealized capital appreciation), and has a reasonable expectation of reaching the same
income level in the current year.

 

		 ̈	The undersigned is a director or executive officer of the Company.

 

		 ̈	The undersigned is either: (a) a bank as defined in Section 3(a)(2) of the Securities Act of 1933,
as amended (the “Act”); (b) a savings and loan association or other institution as defined in Section
3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity; (c) a broker dealer registered pursuant to Section
15 of the Securities Exchange Act of 1934; (d) an insurance company as defined in Section 2(13) of the Act; (e) an investment company
registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of the Act;
(f) a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small
Business Investment Act of 1958; (g) a plan established and maintained by a state, its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions, for the benefit of its employees, if such a plan has total assets in
excess of $5,000,000; or (h) an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974
(“ERISA”), if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA,
which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit
plan has total assets in excess of $5,000,000, or, if a self-directed plan, with investment decisions made solely by persons that
are accredited investors, as defined in Rule (501)(a) promulgated under the Act.

 

(describe
entity)

 

    	16

    	 

    
  

		 ̈	The undersigned is a private business development company as defined in Section 202(a)(22) of the
Investment Advisers Act of 1940.

 

 

(describe
entity)

 

		 ̈	The undersigned is an organization within the meaning of Section 501(c)(3) of the Internal Revenue
Code, a corporation, a business trust, or a partnership, not formed for the specific purpose of acquiring the Securities, with
total assets in excess of $5,000,000.

 

 

(describe
entity)

 

		 ̈	The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific
purpose of acquiring the Securities, whose investments are directed by a “sophisticated person” as described
in Rule 506(b)(2)(ii) promulgated under the Act.

 

		 ̈	The undersigned is an entity, all the equity owners of which are “accredited investors”
within one or more of the above categories. If relying upon this category alone, each equity owner must complete a separate
copy of this Certificate.

 

 

(describe
entity)

 

		 ̈	The undersigned does not meet the criteria of any of the categories listed above.

 

 

THE UNDERSIGNED UNDERSTANDS THAT THE COMPANY
WILL RELY ON THE FOREGOING REPRESENTATIONS TO, AMONG OTHER THINGS, MAINTAIN THE EXEMPTION FOR THE ISSUANCE OF THE SECURITIES FROM
THE REQUIREMENT TO REGISTER SUCH SECURITIES UNDER THE ACT.

 

The answers to the
foregoing questions are correctly stated to the best of my knowledge, information and belief. I hereby agree to notify the Company
promptly of any changes in the foregoing information.

 

Dated: ________________

Name of Purchaser: __________________________________

 

Signature of Authorized Signatory of
Purchaser: _________________________________

 

Name of Authorized Signatory: ____________________

 

Title of Authorized Signatory: ________

 

    	17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]